Takashi Takenoshita

Takashi Takenoshita

CEO

Takashi Takenoshita is a seasoned biotech CEO with over 30 years of experience in the pharmaceutical industry. Before joining Senya in 2022, Takashi was a Venture Partner at Oxford Science Enterprises and co-founder and CEO of Dark Blue Therapeutics, an Oxford University spinout. Previsouly, he held senior executive positions including SVP Head of International at Arena Pharmaceuticals (acquired by Pfizer), co-founder and CEO of Shionogi Europe and Partner at McKinsey & Company. Takashi holds an MsC from London School of Hygiene and Tropical Medicine and a BA from Brown University.

Professor John Greenwood

Professor John Greenwood

Co-founder, Co-CSO

Professor John Greenwood is a vascular biologist with a strong research background in biomedical and translational research. After completing his PhD at the University of London he continued his postdoctoral training at Kings College London before taking up a faculty position at the UCL Institute of Ophthalmology. He was a member of the board of management of the UCL institute of Ophthalmology and spent 8 years as Head of the Department of Cell Biology. He is one of the scientific co-founders of Senya Therapeutics.

Professor Emeritus Steve Moss

Professor Emeritus Steve Moss

Co-founder, Co-CSO

Professor Emeritus Stephen Moss has a background in protein biochemistry and molecular biology. Steve did his PhD in Edinburgh, then after post-doctoral work at ICRF (now CRUK) he then moved to a Faculty position at UCL where he became Head of the Cell Biology Department at the Institute of Ophthalmology and Vice-Dean Enterprise. He is one of the scientific co-founders of Senya.

Dr. Chris Martin

Dr. Chris Martin

Non-Executive Director

Dr. Chris Martin is a seasoned biotech entrepreneur and board member with extensive industry experience. He currently serves as Chair of Myricx Therapeutics and Tagworks Pharmaceuticals and as a Non-Executive Director. Previously, he co-founded ADC Therapeutics and served as its CEO. Earlier in his career, he co-founded Spirogen, leading the company as CEO until its acquisition by AstraZeneca. Chris holds a PhD from the University of Oxford and an MBA from IMD.

Dr. Tanel Ozdemir

Dr. Tanel Ozdemir

Non-Executive Director

Tanel is an investor at AlbionVC and works within the UCL Technology Fund where he supports academics looking to translate next-generation therapeutics. Tanel joined AlbionVC in 2018 after completing his PhD and postdoctoral research at UCL, which focused on developing synthetic biological tools for microbiome engineering. He also holds an MSc in Nanotechnology and Regenerative Medicine from UCL, and a BSc in Human Biology from King’s College London.

Dr. Mark Fisher

Dr. Mark Fisher

Non-Executive Director

Mark is Associate Director of Biopharma at UCL Business and represents UCL Business in Senya’s Board. Mark has a distinguished career in venture investment and management as well as university technology transfer. Mark earned PhD in molecular biology from UCL.

Takashi Takenoshita

Takashi Takenoshita

Executive Director

Takashi Takenoshita is a seasoned biotech CEO with over 30 years of experience in the pharmaceutical industry. Before joining Senya in 2022, Takashi was a Venture Partner at Oxford Science Enterprises and co-founder and CEO of Dark Blue Therapeutics, an Oxford University spinout. Previously, he held senior executive positions, including SVP Head of International at Arena Pharmaceuticals (acquired by Pfizer), co-founder and CEO of Shionogi Europe and Partner at McKinsey & Company. Takashi holds an MSc from the London School of Hygiene and Tropical Medicine and a BA from Brown University.

About us

Senya Therapeutics is pioneering an anti-leucine-rich α-2 glycoprotein 1 (LRG1) therapeutic platform to address major unmet clinical needs in nephrology, oncology, pulmonary disease and ophthalmology.

Targeting LRG1 represents a new paradigm in the treatment of chronic disease, Senya Therapeutics (formerly Panangium Therapeutics) was founded in 2023 as a spin-out from University College London, UK building on inherited data accumulated over 15 years of world-leading research.

Who We Are

This know-how has translated into an extensive portfolio of patents related to therapeutic targeting of LRG1, enabling our first-in-class – best-in-class position. In addition to our lead asset a pipeline of new innovative anti-LRG1 biologics is being developed that will maintain our place at the forefront of LRG1 targeted therapy. The Company is led by a highly experienced Management Team, Board of Directors and supported by an Scientific Advisory Board comprising renowned international key opinion leaders.

Management Team

Takashi Takenoshita
Takashi Takenoshita

CEO

Professor John Greenwood
Professor John Greenwood

Co-founder, Co-CSO

Professor Emeritus Steve Moss
Professor Emeritus Steve Moss

Co-founder, Co-CSO

Board members

Dr. Chris Martin
Dr. Chris Martin

Non-Executive Director

Dr. Tanel Ozdemir
Dr. Tanel Ozdemir

Non-Executive Director

Dr. Mark Fisher
Dr. Mark Fisher

Non-Executive Director

Takashi Takenoshita
Takashi Takenoshita

Executive Director

Advisors

Nephrology

Professor Neeraj Dhaun

University of Edinburgh; Director, Edinburgh Clinical Research Facility

Dr. Steve McAdoo

Consultant Nephrologist and Honorary Clinical Senior Lecturer, Imperial College London

Oncology

Professor Christian Blank

The Netherlands Cancer Institute

Professor Timothy Yap

University of Texas; previously MD Anderson Cancer Center

Professor Emeritus Adrian Harris

University of Oxford

Translational medicine

Dr. Pete Charlton

Experienced pharmaceutical R&D executive; previously Vertex, Imperial Innovations, Kesios Therapeutics, GSK

Dr. Glen Clack

Oncology translational medicine specialist; previously AstraZeneca

Intellectual property

Dr. Richard Warburg

Patent attorney, VC investor and board member; previously Foley and Lardner, Lyon and Lyon

Dr. Jim MacDonald

Patent attorney, Altitude Life Science Ventures; previously Wilson Sonsini Goodrich & Rosati, Juno Therapeutics, Sana Biotechnology

Dr. Lucy Williams

Patent attorney; previously JA Kemp

Our story

2010 - 2021

£10.5M academic grants (including from Medical Research Council, Wellcome Trust, British Heart Foundation) to research LRG1 in disease and developing therapies.

2013

Nature publication of LRG1 paper

2015

Development of STX-001 (Magacizumab)

2019

Spinout from UCL as LRG1 Limited; Trading as Panangium therapeutics focusing on eye disease

2019

Additional £1M seed funding from UCL Tech Fund to commence cancer research

2022

Strategy expansion in view of emerging opportunities in multiple indications

Takashi Takenoshita joins as CEO

2023

Launched as Senya Therapeutics and pursues LRG1 platform strategy with new focus on Nephrology and Oncology

2024

Raises £2M Seed extension, including $1M grant from Innovate UK

Dr. Chris Martin joins as non-executive director

2024

Starts collaboration with Imperial College London and the University of Edinburgh to develop kidney therapeutics

2025

Starts collaboration with the Netherlands Cancer Institute (NKI)

NKI takes an equity stake in Senya

2025

Completing preclinical programme for STX-001 in Nephrology and Oncology

Launched the development of STX-002 and 003

Our Investors